Wellness and Prevention in Chronic Disease Consensus Statement

Supplements
Download PDF
Gary M. Owens, MD
Nirav R. Shah, MD, MPH, FACP
Michael McLean, RPh, MPA
Kip Piper, MA, FACHE
Doug Burgoyne, PharmD
John Fox, MD
Stacie Heller
Wayne M. Lednar, MD, PhD
Lynne Rothney-Kozlak
Scott R. Taylor, RPh, MBA
F. Randy Vogenberg, RPh, PhD

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: September 30th, 2010 - September 30th, 2011

Target Audience
This activity was developed for physicians, pharmacists, and other healthcare professionals practicing in a managed care environment.

 

Learning Objectives
At the completion of this activity participants should be able to:

  • Increase awareness of the personal, social, and economic burden of chronic diseases and determine its impact on the patient, family, society, and workplace
  • Identify risk factors for disease and, conversely, wellness and prevention processes and initiatives
  • Propose clinical, business, and policy responses in addressing geographic and racial/ethnic disparities in health and healthcare delivery, especially in terms of capitalizing on successful wellness initiatives already achieved in the private and public sectors
  • Encourage early recognition and treatment of illnesses to reduce future economic costs.

 

Estimated time to complete this activity: 1 hour

 

Physician Credit Designation
The University of Cincinnati designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in this activity.

 

Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-10-028-H01-P.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

Loretta Fala has nothing to disclose.

The University of Cincinnati, the associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

 

Faculty Disclosures
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.

Nirav R. Shah, MD, MPH, is on the Speaker's Bureau for Johnson & Johnson, Medical Learning Institute, Inc., and Takeda; he receives unrestricted research grant support from AstraZeneca and the PATH Foundation and is a Consultant to FAIR Health.
*MichaelMcLean, RPh, MPA, has nothing to disclose.
Kip Piper, MA, FACHE, is a Consultant to Abbott, Genzyme, Novo Nordisk, and Philips Healthcare.
Doug Burgoyne, PharmD, is a Consultant to Dymaxium, Eli Lilly, and GlaxoSmithKline.
John Fox, MD, has nothing to disclose.
Stacie Heller, has nothing to disclose.
Wayne M. Lednar, MD, PhD, has nothing to disclose.
Lynne Rothney-Kozlak, has nothing to disclose.
Scott R. Taylor, RPh, MBA, has nothing to disclose.
F. Randy Vogenberg, RPh, PhD, is on the Speaker's Bureau for Boehringer Ingelheim, a Consultant for Pfizer, a Consultant and Trainer for Genentech, and a Trainer for Allergan.

*Content will include non-FDA-approved uses.

 

Disclaimer
The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Trade names used in this supplement are for the learner's reference only. No promotion of or bias toward any product should be inferred.

Related Items
New Directions in the Treatment and Symptom Management of Multiple Sclerosis – Part 2
Samuel F. Hunter, MD, PhD, Gary M. Owens, MD
Interactive Learning published on June 13, 2013
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost-Effective Management of Myelofibrosis
Gary M. Owens, MD, Alfonso Quintas-Cardama, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Payer Perspective ASH 2011 Update: Strategies for Value-Based Care for Patients with Myelofibrosis
John Fox, MD, Michael J. Mauro, MD
Supplements published on April 30, 2012
Overcoming Racial, Ethnic, and Geographic Healthcare Disparities in the Management of Patients with Chronic Non-Cancer Pain
Alberto M. Colombi, MD, Kip Piper, MA, FACHE, Ernest Moy, MD, MPH
Supplements published on November 21, 2011
Optimizing New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis in Managed Care
Gary M. Owens, MD, Bruce L. Hughes, MD , Sonya J. Lewis, RPh, MBA
Supplements published on August 2, 2011
ASH 2010 Update on Multiple Myeloma: Treatment Trends and Strategies for Value-Based Care
John Fox, MD, James T. Kenney Jr, RPh, MBA
Supplements published on March 4, 2011
ASH 2010 Update on Non-Hodgkin Lymphoma: Alignment of the Current Treatment Landscape and Value-Based Care
John Fox, MD, James T. Kenney Jr, RPh, MBA
Supplements published on February 28, 2011
Considerations in Multiple Myeloma: Case Studies in Cytogenetics
Ajai Chari, MD, Keren Osman, MD, Michael McLean, RPh, MPA, Denise O'Dea, ARNP-BC, OCN
Supplements published on October 14, 2010
Highlights from ASCO 2010: An Update for Payers and Providers on Chronic Myelogenous Leukemia
Gary M. Owens, MD, Michael Mauro, MD
Supplements published on September 15, 2010
Last modified: March 21, 2014